Ontology highlight
ABSTRACT: Background
Surgical resection provides the only potentially curative treatment of pancreatic cancer. Neoadjuvant chemotherapy and/or radiation (NAT) is used to downstage patients with borderline resectable tumors. The objective of this study was to examine the postoperative morbidity and mortality of NAT after pancreaticoduodenectomy (PD) for pancreatic ductal adenocarcinoma (PDA).Methods
Using the American College of Surgeons-National Surgical Quality Improvement Project Targeted Pancreatectomy data, we identified patients who underwent a PD for PDA from 2014 to 2015. Patients were grouped by receipt of NAT 90 days before PD. Bivariable and multivariable analyses was used to compare postoperative outcomes.Results
A total of 3748 patients with PDA underwent PD; 926
SUBMITTER: Cools KS
PROVIDER: S-EPMC6653597 | biostudies-literature | 2018 Sep
REPOSITORIES: biostudies-literature